Vitamin D & Longevity: The Hormone-Vitamin That 42% of Americans Are Deficient In

If there is one lab value I could require every patient to know, it would be their 25-OH vitamin D level. Not their cholesterol. Not their fasting glucose. Vitamin D — because the downstream consequences of chronic deficiency touch virtually every organ system relevant to longevity, the deficiency is nearly universal in modern populations, and the correction is cheap, safe, and measurably effective. I have been running 25-OH vitamin D on every patient in my practice for over a decade, and the percentage who walk in suboptimal is consistently above 60% — this in Michigan, a northern latitude state where sun exposure is limited for six months per year.

The challenge is that even patients who “pass” the standard lab reference range are often far from optimal. A level of 21 ng/mL is technically “sufficient” by outdated criteria — but the epidemiological data associating vitamin D levels with all-cause mortality, cancer incidence, cardiovascular events, and cognitive decline points consistently toward a target of 50–80 ng/mL. The gap between “not deficient” and “optimized” is not semantic — it represents years of healthy function at the tail of a life.

Why Vitamin D Is Actually a Steroid Hormone, Not a Vitamin

The name “vitamin D” is a historical misnomer. True vitamins are organic compounds that the body cannot synthesize and must obtain from diet. Vitamin D, by contrast, is synthesized endogenously when UVB radiation from sunlight strikes the skin and converts 7-dehydrocholesterol (a cholesterol precursor) into pre-vitamin D3, which then undergoes thermal isomerization to cholecalciferol (D3). This synthesized cholecalciferol is then hydroxylated in the liver to 25-hydroxyvitamin D (25-OH-D), the storage form measured in standard blood tests, and subsequently activated in the kidneys — and increasingly, in peripheral tissues — to 1,25-dihydroxyvitamin D (calcitriol), the active hormone.

Calcitriol binds to the vitamin D receptor (VDR), a nuclear receptor in the same family as testosterone and cortisol receptors. The VDR is expressed in over 36 different tissue types — including the heart, brain, immune cells, colon, breast, prostate, muscle, and blood vessels. When calcitriol binds the VDR, the receptor-hormone complex translocates to the nucleus and regulates gene transcription. Current genomic analysis estimates that vitamin D regulates the expression of more than 2,000 human genes — roughly 10% of the genome. This level of regulatory reach is characteristic of a master hormone, not a micronutrient.

Understanding this reclassification has practical implications for supplementation. You cannot optimize a hormone-level intervention by treating it as a simple dietary supplement. Vitamin D requires cofactors (particularly vitamin K2 and magnesium) for full biological activity, has dose-response relationships that differ from classical vitamins, and requires monitoring via blood levels rather than simple dietary intake tracking. The pharmacology of vitamin D optimization is fundamentally closer to thyroid hormone management than to supplementing vitamin C.

The Scale of Deficiency: Who Is Most at Risk and Why

The NHANES (National Health and Nutrition Examination Survey) data documenting widespread vitamin D deficiency in the United States is striking. Analysis of the 2001–2006 NHANES dataset, published in Nutrition Research in 2011, found that 41.6% of American adults had serum 25-OH-D levels below 20 ng/mL — the threshold conventionally used to define deficiency. When optimal levels (≥50 ng/mL) are used as the criterion, over 85% of Americans fall short. This is not a marginal public health concern — it is near-universal functional hormone deficiency in a developed nation.

Who Is Most Deficient

Deficiency rates are not uniform across the population. The groups at highest risk include: individuals with darker skin pigmentation (melanin blocks UVB penetration — Black Americans have deficiency rates of 82%, Hispanic Americans 70%, compared to 32% in non-Hispanic whites); residents of northern latitudes above 35 degrees (Michigan, New York, Chicago — where UVB-sufficient sunlight is unavailable from October through March); obese individuals (vitamin D is fat-soluble and sequestered in adipose tissue, reducing bioavailability); older adults (skin synthesis efficiency declines by 75% between age 20 and 70, and kidney activation of 25-OH-D is impaired in aging); patients with malabsorption conditions (Crohn’s disease, celiac, bariatric surgery); and — importantly — office workers of any background, given that glass blocks UVB radiation entirely and modern indoor lifestyles eliminate the sun exposure our evolutionary biology assumed.

Why Modern Life Guarantees Deficiency

The evolutionary context helps explain the scale of the problem. Homo sapiens evolved at equatorial latitudes, spending the majority of daylight hours outdoors with significant skin exposure. Anthropological estimates suggest our ancestral baseline vitamin D level was 40–80 ng/mL — sustained by daily skin synthesis during outdoor activity. Modern indoor living, the shift to northern latitudes, sunscreen use, and clothing coverage have dismantled the primary mechanism by which our bodies were designed to maintain this hormone. The result is that modern humans are chronically operating with vitamin D levels 50–70% below our evolutionary norm — and our disease epidemics in cardiovascular disease, cancer, autoimmunity, and neurodegenerative disease may be partly a reflection of that hormonal gap.

Testing and Optimal Ranges: Moving Beyond the “Normal” Threshold

The test you want is the 25-hydroxyvitamin D (25-OH-D), also written as 25(OH)D, available at any standard lab. This is the stable storage form that reflects total vitamin D status from both sun synthesis and supplementation, and it has the longest half-life (~15 days), making it the clinically informative circulating marker. The activated form, 1,25-dihydroxyvitamin D (calcitriol), is NOT the test you want for assessing deficiency — its levels are often normal or even elevated in deficiency states because the body upregulates conversion when stores are low. Requesting “vitamin D, 25-OH” specifically ensures you get the right test.

Understanding the Reference Ranges

Standard lab reference ranges define vitamin D sufficiency as ≥20 ng/mL, with deficiency below 20 ng/mL and severe deficiency below 10 ng/mL. These cutoffs were established primarily to define the minimum level preventing rickets and osteomalacia — skeletal disorders driven by severe calcium-phosphate dysregulation. They are not based on cardiovascular outcomes, cancer risk, cognitive function, or any other non-skeletal endpoint relevant to longevity.

When researchers examine all-cause mortality against 25-OH-D levels, the nadir of the U-shaped mortality curve consistently falls between 40 and 80 ng/mL. A landmark 2014 meta-analysis in the British Medical Journal pooled data from 73 observational studies and found that all-cause mortality increased progressively as 25-OH-D declined below 40 ng/mL — with the steepest mortality increase below 20 ng/mL, but continued risk elevation between 20 and 40 ng/mL. The practical implication: achieving the lab “normal” of 20 ng/mL is not clinical success for longevity medicine. It is barely clearing the floor.

My clinical targets, based on the evidence base: Minimum adequate: 40 ng/mL. Longevity-optimal: 50–70 ng/mL. Upper caution threshold: 100 ng/mL (toxicity risk begins to emerge above this level with chronic over-supplementation, though it takes sustained doses of 10,000+ IU/day to reach). For most patients, targeting 60 ng/mL gives adequate buffer below toxicity while maximizing the non-skeletal benefits across cardiovascular, immune, cancer-protective, and neurological endpoints.

Vitamin D and Cardiovascular Health: The All-Cause Mortality Data

Cardiovascular disease remains the leading cause of death in the United States, and the association between vitamin D deficiency and cardiovascular outcomes is one of the most replicated findings in epidemiology. The Framingham Offspring Study, published in Circulation in 2008, followed 1,739 participants free of cardiovascular disease for a mean of 5.4 years. Those with 25-OH-D levels below 15 ng/mL had a 1.62-fold higher risk of a first cardiovascular event compared to those with levels ≥15 ng/mL — an association that remained significant after adjustment for traditional cardiovascular risk factors including hypertension, diabetes, BMI, and lipid levels.

Hypertension and the Renin-Angiotensin System

The cardiovascular mechanisms of vitamin D are multifaceted. The best characterized involves the renin-angiotensin-aldosterone system (RAAS) — the hormonal cascade that governs blood pressure. Vitamin D directly suppresses renin production in the kidneys: VDR activation downregulates the renin gene, reducing the production of angiotensin II, a potent vasoconstrictor. Low vitamin D effectively takes the brake off the RAAS, allowing renin levels to rise, blood pressure to increase, and vascular remodeling to accelerate.

Animal studies with VDR-knockout mice confirm this mechanism elegantly: mice lacking functional vitamin D receptors develop renin-dependent hypertension and cardiac hypertrophy. Human intervention studies show that vitamin D supplementation in deficient patients reduces systolic blood pressure by a mean of 2–6 mmHg — modest but clinically meaningful at a population level, where a 5 mmHg reduction in systolic pressure reduces stroke risk by approximately 14% and coronary artery disease risk by approximately 9%.

Endothelial Function and Atherosclerosis

Beyond blood pressure, vitamin D promotes endothelial health through several mechanisms: it reduces expression of adhesion molecules (ICAM-1, VCAM-1) that recruit inflammatory monocytes to vessel walls and initiate atherosclerotic plaques; it suppresses foam cell formation and macrophage-driven plaque progression; and it reduces platelet aggregation and thrombotic tendency. A 2013 meta-analysis in Atherosclerosis found that each 10 ng/mL increase in 25-OH-D was associated with a 10% lower risk of coronary artery disease in prospective studies.

The prospective VITAL trial — a landmark randomized controlled trial of 25,871 participants — tested vitamin D3 at 2,000 IU/day over 5.3 years. The cardiovascular findings were nuanced: there was no significant reduction in major cardiovascular events in the primary analysis of the full cohort, but a pre-specified subgroup analysis found a significant 22% reduction in major cardiovascular events in participants with BMI below 25. The subgroup finding suggests that vitamin D’s cardiovascular benefit may be most pronounced in lean individuals without the adipose tissue sequestration that limits bioavailability at standard doses — and that higher doses may be needed to overcome the dilution effect in obesity.

Vitamin D and Cancer Prevention: The VITAL Trial and Beyond

Cancer is the second leading cause of death in the United States and the most feared diagnosis in medicine. The relationship between vitamin D and cancer risk is one of the most extensively studied — and most consequential — areas in nutritional oncology. The foundational observation, first made by epidemiologists Cedric and Frank Garland in 1980, was that colon cancer mortality was inversely correlated with sun exposure across geographic regions in the United States: states with more sun had significantly lower colon cancer death rates. This observation launched decades of research confirming and expanding the vitamin D-cancer connection across multiple tumor types.

The VITAL Trial: The Definitive RCT Data

The VITAL (VITamin D and OmegA-3 TriaL) study, published in the New England Journal of Medicine in 2019, is the largest and most rigorously designed randomized controlled trial of vitamin D supplementation for cancer prevention ever conducted. It enrolled 25,871 participants (mean age 67) with no prior history of cancer and randomized them to vitamin D3 at 2,000 IU/day or placebo for a median follow-up of 5.3 years.

The primary cancer incidence endpoint — total cancer diagnosis — was not significantly reduced (hazard ratio 0.96, 95% CI 0.88–1.06). However, two critical secondary findings have reshaped clinical practice. First, cancer mortality was reduced by 25% in the vitamin D group (HR 0.75, 95% CI 0.59–0.96, p=0.02). This means that while vitamin D at 2,000 IU did not prevent cancer from developing, it dramatically altered the biology of cancers that did develop — reducing their lethality by one quarter. Second, the mortality reduction was even larger in participants who were not obese: a 38% reduction in cancer mortality in normal-weight participants. The dose of 2,000 IU was likely insufficient to achieve target levels in obese participants, further supporting the case for dose titration to achieve target serum levels rather than using flat-dose supplementation.

Mechanisms: How Vitamin D Suppresses Tumor Biology

The anti-cancer mechanisms of vitamin D are well characterized at the molecular level. Calcitriol (activated vitamin D) exerts anti-proliferative effects by upregulating p21 and p27 — cell cycle checkpoint proteins that arrest tumor cell division. It promotes differentiation (pushing immature tumor cells toward more normal phenotypes) and apoptosis (programmed tumor cell death) through Bcl-2 suppression. Critically, it suppresses tumor angiogenesis — the formation of new blood vessels that feed growing tumors — by downregulating VEGF (vascular endothelial growth factor) expression. And it reduces prostaglandin E2 production via cyclooxygenase-2 suppression, reducing the inflammatory tumor microenvironment that promotes metastatic spread.

The cancer types with strongest vitamin D evidence include colorectal (25–35% risk reduction per meta-analysis), breast (meta-analyses consistently showing 30–50% lower risk in highest vs. lowest 25-OH-D quartiles), prostate (inverse correlation with advanced disease), and pancreatic cancer. The data on colorectal cancer is particularly robust: the VDR is highly expressed in colonic epithelium, and the Garland-inspired mechanism — vitamin D promoting normal differentiation of colonic epithelial cells and suppressing hyperproliferative precancerous changes — has been repeatedly validated in both animal models and human intervention studies.

Vitamin D and Immune Function: From COVID-19 to Autoimmunity

The immune system is perhaps the most vitamin D-sensitive non-skeletal organ system in the human body. Every cell in the adaptive immune system — T cells, B cells, natural killer cells, dendritic cells — expresses the vitamin D receptor, and calcitriol regulates both the innate and adaptive arms of immune function in ways that are anti-inflammatory without being immunosuppressive. This nuance is critical: vitamin D doesn’t simply quiet immune activity — it reshapes immune activity toward greater precision and less collateral inflammatory damage.

Innate Immunity and Antimicrobial Defense

Vitamin D directly induces the synthesis of cathelicidin (LL-37) and beta-defensin 2 — endogenous antimicrobial peptides that kill bacteria, viruses, and fungi on contact. This mechanism explains the well-established epidemiological observation that respiratory infection rates peak in winter months — not because cold air causes infections, but because reduced winter sun exposure depletes vitamin D and compromises the innate immune front line. A 2017 systematic review and meta-analysis in the British Medical Journal analyzed 25 randomized trials covering 11,321 participants and found that vitamin D supplementation reduced the risk of acute respiratory tract infection by 12% overall — with a 58% risk reduction in individuals who were severely deficient at baseline (25-OH-D below 10 ng/mL).

Autoimmune Disease Prevention

The strongest emerging evidence for vitamin D’s immune benefits may be in autoimmune disease prevention. The VITAL trial’s autoimmunity sub-study, published in the New England Journal of Medicine in 2022 (Hahn et al.), is the first large RCT to demonstrate that vitamin D supplementation significantly reduces the risk of developing autoimmune disease. After 5+ years of follow-up, the vitamin D3 group had a 22% lower incidence of confirmed autoimmune diseases — including rheumatoid arthritis, psoriasis, polymyalgia rheumatica, thyroid disease, and inflammatory bowel disease — compared to the placebo group. The fish oil + vitamin D combination produced a 31% reduction. This is the first randomized evidence that a nutritional intervention can meaningfully reduce the lifetime risk of autoimmune disease in adults.

The mechanistic explanation involves vitamin D’s role in regulatory T cell (Treg) biology. Calcitriol promotes the differentiation of naive T cells toward Tregs — the immune cells that enforce self-tolerance and prevent the immune system from attacking the body’s own tissues. Low vitamin D shifts T cell differentiation away from Tregs and toward Th1/Th17 cells, the effector cells responsible for the inflammatory tissue destruction characteristic of autoimmune conditions. Geographic and epidemiological data strongly support this model: autoimmune disease prevalence rises dramatically at higher latitudes, and the highest-prevalence regions globally are northern Europe, Canada, and the northern United States — exactly where vitamin D deficiency is most prevalent.

Vitamin D and Brain Health: Cognition, Depression, and Dementia Risk

The brain is rich with VDR-expressing neurons, particularly in the hippocampus, prefrontal cortex, cingulate gyrus, and thalamus — regions central to memory, executive function, mood regulation, and consciousness. Calcitriol in the brain serves as a neuroprotective steroid, regulating neurotrophic factor synthesis (particularly NGF and GDNF), modulating calcium homeostasis in neurons, suppressing neuroinflammation via NF-κB inhibition, and clearing amyloid-beta. The brain’s vitamin D dependency has significant implications for both mental health and long-term cognitive longevity.

Depression and Mood Regulation

The association between vitamin D deficiency and depression is well established epidemiologically. A 2013 meta-analysis in the British Journal of Psychiatry pooled data from 14 studies involving 31,424 participants and found that individuals in the lowest vitamin D quartile had a 1.31-fold higher risk of depression compared to the highest quartile. Seasonal affective disorder (SAD) — depression with a winter-dominant pattern — is arguably the most clinically obvious manifestation of vitamin D’s role in mood, though melatonin disruption and circadian rhythm disruption from reduced light exposure contribute independently.

Mechanistically, vitamin D regulates tyrosine hydroxylase — the rate-limiting enzyme in dopamine and norepinephrine synthesis. Low vitamin D reduces dopaminergic tone in the mesolimbic reward system, contributing to anhedonia, low motivation, and depressive symptomatology. Vitamin D also supports serotonin synthesis and the serotonin transporter, providing additional mood-regulatory mechanistic overlap. A 2014 review in the FASEB Journal proposed a detailed “serotonin theory” of vitamin D’s mood effects, linking the hormone’s regulation of tryptophan hydroxylase 2 to serotonin production in the brain.

Cognitive Decline and Dementia Prevention

The link between vitamin D status and cognitive decline has strengthened substantially over the past decade. A 2014 prospective study in Neurology (Littlejohns et al.) followed 1,658 elderly adults free of dementia at baseline for a mean of 5.6 years. Those who were severely deficient (25-OH-D below 25 nmol/L, ~10 ng/mL) had a 122% increased risk of all-cause dementia and a 122% increased risk of Alzheimer’s disease compared to sufficient individuals (≥75 nmol/L, ~30 ng/mL). Even those with moderately deficient levels (25–50 nmol/L) had a 53% increased dementia risk and 69% increased Alzheimer’s risk.

The mechanisms are multiple: vitamin D induces macrophage-mediated amyloid clearance, reduces tau phosphorylation (a driver of neurofibrillary tangle formation), suppresses neuroinflammatory microglial activation, and promotes neurotrophic factor expression that supports neuronal survival and synaptic plasticity. A 2023 large Mendelian randomization study in the American Journal of Clinical Nutrition found genetic evidence consistent with a causal role for low vitamin D in dementia risk — strengthening the epidemiological associations with a design less susceptible to confounding.

Optimal Dosing: D3, K2, Magnesium, and Why Form and Cofactors Matter

Optimizing vitamin D is not as simple as taking a capsule. The form of vitamin D, the dose required to achieve target serum levels, and the cofactors needed for full biological activity all require understanding. Getting this wrong means either underdosing (failing to reach target serum levels), missing the K2 cofactor (and potentially misrouting calcium into arteries rather than bone), or failing to account for magnesium depletion that limits vitamin D activation.

Vitamin D3 vs. D2: Always Choose D3

Vitamin D comes in two supplemental forms: D2 (ergocalciferol, derived from fungal/plant sources) and D3 (cholecalciferol, derived from lanolin/animal sources). These are not pharmacologically equivalent. A 2011 study in the Journal of Clinical Endocrinology & Metabolism directly compared D2 and D3 supplementation and found that D3 raised serum 25-OH-D levels approximately 87% more effectively than D2 at equivalent doses. D3 also has a substantially longer half-life and produces a more sustained elevation in circulating 25-OH-D. Prescription vitamin D in the United States is almost universally D2 (ergocalciferol at 50,000 IU weekly) — despite the evidence that D3 is superior. Always use vitamin D3 for supplementation unless you have a specific reason to use D2.

Dosing Strategy: Target the Level, Not the Dose

The most important principle in vitamin D dosing is that the dose required to achieve a target serum level varies enormously between individuals — driven by baseline level, body weight, adipose tissue volume, sun exposure, genetic VDR polymorphisms, and gut absorption. A 2,000 IU daily dose may achieve 60 ng/mL in a lean, sun-exposed young adult and only 30 ng/mL in an obese, indoor-dwelling middle-aged patient in Michigan. For this reason, the clinical approach is: start supplementation, test at 8–12 weeks, adjust dose to hit 50–70 ng/mL, then test annually.

General starting dose guidance: for adults with confirmed deficiency (below 30 ng/mL), 4,000–5,000 IU vitamin D3 daily is typically required to achieve optimal levels in 8–12 weeks. For maintenance once optimal levels are achieved, 2,000–3,000 IU daily is usually sufficient in normal-weight adults, with higher doses needed in obesity (BMI >30) due to adipose sequestration. Weekly high-dose loading protocols (50,000 IU D3 weekly for 8–12 weeks) are used in clinical practice for rapid repletion of severe deficiency and are safe in the context of appropriate monitoring. Doses above 5,000 IU daily should be accompanied by serum monitoring at 3-month intervals.

The Critical Role of Vitamin K2

Vitamin D3 supplementation without adequate vitamin K2 creates a biochemical mismatch that may increase arterial calcification risk. Here’s the mechanism: vitamin D increases intestinal calcium absorption. The absorbed calcium must be directed to bone (where it strengthens skeletal structure) rather than to arterial walls (where it stiffens arteries and drives cardiovascular disease). This routing is governed by two vitamin K2-dependent proteins: osteocalcin (which binds calcium into bone matrix) and Matrix Gla Protein (MGP, which actively inhibits calcium deposition in arterial walls). Both proteins require vitamin K2 for carboxylation into their active, calcium-binding forms. Without K2, they remain inactive — calcium absorption increases (vitamin D effect) but it cannot be properly deposited in bone or excluded from arteries.

The Rotterdam Study, a prospective cohort of 4,807 participants, found that dietary vitamin K2 (menaquinone) was inversely associated with aortic calcification and all-cause mortality, independent of vitamin K1 intake. For supplementation, vitamin K2 as MK-7 (menaquinone-7) is the preferred form — it has a 72-hour half-life versus 2 hours for MK-4, and a single daily dose of 100–200 mcg MK-7 effectively carboxylates osteocalcin and MGP throughout the day. I recommend 100 mcg MK-7 for patients on 2,000–3,000 IU vitamin D3 daily, and 200 mcg MK-7 for patients on 4,000–5,000 IU. Note: MK-7 has mild anticoagulant activity and should be discussed with physicians managing patients on warfarin.

Magnesium: The Cofactor That Activates Vitamin D

Vitamin D cannot be fully activated without magnesium. The conversion of 25-OH-D (storage form) to 1,25-OH-D (active calcitriol) by the enzyme CYP27B1 in the kidney requires magnesium as a cofactor. Patients who are both magnesium-deficient and vitamin D-deficient — which, given their overlapping epidemiology, is extremely common — may respond poorly to vitamin D supplementation until magnesium status is corrected. A 2018 analysis in the American Journal of Clinical Nutrition found that adequate magnesium intake was associated with significantly higher conversion of 25-OH-D to its active form and lower conversion to the catabolite 24,25-OH-D. If your vitamin D levels aren’t responding to supplementation as expected, check RBC magnesium — it is often the limiting factor.

The Clinical Connection: Vitamin D in Podiatry and Foot Surgery

As a podiatric surgeon who has performed over 3,000 foot and ankle procedures, I encounter the consequences of vitamin D deficiency in the lower extremities more frequently than any other nutritional deficiency. The foot and ankle are disproportionately affected by vitamin D’s skeletal and soft tissue effects for a simple anatomical reason: these structures bear 100% of body weight with every step, subjecting bone to mechanical loading that amplifies any structural compromise from inadequate mineralization. A vitamin D deficiency that might be subclinical in the non-weight-bearing spine can manifest as frank fracture risk in the foot.

Stress Fractures and Bone Density

Stress fractures of the metatarsals — the thin bones in the midfoot that transmit force with each step — are among the most common injuries I treat. While repetitive mechanical loading is the proximate cause, vitamin D deficiency is a major modifiable predisposing factor. Calcitriol drives intestinal calcium absorption (responsible for 30–40% of dietary calcium uptake at optimal D levels versus only 10–15% at deficient levels) and promotes osteoblast-mediated bone matrix synthesis. Deficiency produces structurally weaker bone — adequate mineral density on DEXA scanning may mask poor bone quality that does not withstand repetitive loading.

A 2015 study in the American Journal of Sports Medicine measured 25-OH-D levels in 120 athletes presenting with stress fractures and found that 60% had levels below 40 ng/mL. A 2012 systematic review found that athletes with stress fractures had significantly lower vitamin D levels than matched controls without fractures. In my practice, any patient presenting with recurrent stress fractures — more than one metatarsal stress fracture in a 2-year period — receives a complete nutritional panel including 25-OH-D, calcium, phosphorus, and magnesium as standard of care, before I consider any structural or mechanical intervention.

Post-Operative Bone Healing and Fusion Rates

In elective foot and ankle surgery — hammertoe corrections, bunion reconstructions, flatfoot procedures — the outcome of bone work depends critically on the quality of bone healing in the post-operative period. Vitamin D is essential for the callus formation and mineralization phases of fracture healing: osteoblasts express VDR, and calcitriol directly upregulates the expression of bone morphogenetic proteins (BMPs) and collagen type I that drive new bone formation. In vitamin D-deficient patients, callus formation is delayed, mineralization is incomplete, and delayed union and nonunion rates rise.

A 2013 study in the Journal of Bone and Joint Surgery found that patients undergoing elective orthopedic surgery had significantly higher non-union rates when vitamin D levels were below 30 ng/mL at the time of surgery. I now screen all elective surgical patients pre-operatively and will not proceed with elective bone procedures in patients with 25-OH-D below 40 ng/mL until levels are corrected — a protocol change that has meaningfully reduced our rate of wound and healing complications over the past several years.

Diabetic Foot Wounds and Peripheral Neuropathy

Diabetic foot wounds are the leading cause of non-traumatic lower limb amputation in the United States — and virtually all diabetic patients have significant vitamin D deficiency. The connection is bidirectional: vitamin D deficiency worsens insulin resistance and glycemic control (the root driver of diabetic complications), impairs immune-mediated wound defense, reduces the collagen synthesis needed for granulation tissue formation, and suppresses the anti-inflammatory signaling required for orderly wound healing progression. A vitamin D-replete diabetic wound heals dramatically better than a vitamin D-deficient one, all other factors equal.

Additionally, vitamin D plays a direct role in peripheral neuropathy — the nerve damage driving loss of protective sensation that makes diabetic foot wounds so catastrophic. Calcitriol promotes Schwann cell function (the cells that produce the myelin sheath around peripheral nerves) and suppresses the neuroinflammation that drives nerve fiber degradation. Clinical data from our practice shows that diabetic patients with 25-OH-D above 50 ng/mL have significantly lower rates of serious wound complications requiring hospitalization than those with levels below 30 ng/mL — a finding consistent with published literature in wound care journals.

Frequently Asked Questions: Vitamin D and Longevity

Can I get enough vitamin D from sunlight alone?

In theory, yes — but in practice, for the majority of Americans, no. Adequate sun exposure for vitamin D synthesis requires: direct UVB exposure (glass blocks UVB entirely), significant skin exposure (face and hands alone are insufficient — the torso and limbs need to be exposed), at the right time of day (UVB is only adequate when the sun is above 45° elevation — roughly 10am–3pm), at the right latitude (above 35°N, adequate UVB is unavailable from October through March), and without sunscreen (SPF 15 blocks 99% of vitamin D synthesis). The conclusion: for any resident of the northern United States — Michigan, New York, Chicago, Boston — supplementation is effectively mandatory for optimal vitamin D status year-round. Even in southern states, most people spend the majority of their day indoors and cannot rely on sunlight for adequate synthesis.

Is vitamin D toxicity real, and how much is too much?

Vitamin D toxicity (hypervitaminosis D) is real but rare at doses used in clinical practice. Toxicity requires sustained accumulation of vitamin D in adipose tissue over months, driving serum 25-OH-D above 150 ng/mL and producing hypercalcemia — elevated serum calcium that causes nausea, vomiting, weakness, kidney damage, and potentially cardiac arrhythmia. The tolerable upper intake level set by the National Academies is 4,000 IU/day, but this is the level above which monitoring becomes important, not the threshold for actual toxicity. Most published toxicity cases involve daily doses of 10,000+ IU for months without monitoring. At 2,000–5,000 IU/day with periodic serum monitoring to target 50–80 ng/mL, toxicity risk is negligible. The far more common clinical problem is undertreating deficiency out of unfounded toxicity fear.

What are the best dietary sources of vitamin D?

Dietary vitamin D is extremely limited compared to what the body can synthesize from sunlight or obtain through supplementation. The richest sources are wild-caught fatty fish: sockeye salmon (447–988 IU per 3.5 oz serving), swordfish (666 IU), and rainbow trout (645 IU). Canned tuna provides approximately 268 IU per 3 oz. Vitamin D-fortified foods — fortified milk (115–130 IU per cup), fortified orange juice (137 IU per cup), fortified cereals (40–100 IU per serving) — provide modest amounts. The problem: even an optimally vitamin D-rich diet provides 1,000–1,500 IU/day at best — insufficient to maintain 50–80 ng/mL serum levels in most adults, especially at northern latitudes. Diet plus supplementation is required for the majority of people.

Should I take vitamin D with food?

Yes — vitamin D is fat-soluble and absorption is substantially enhanced by dietary fat. A 2015 study in the Journal of the Academy of Nutrition and Dietetics found that taking vitamin D3 with the largest fat-containing meal of the day increased 25-OH-D levels by 50% compared to taking it without food. Take your vitamin D3 + K2 with your largest meal — typically lunch or dinner. If you take it with breakfast, include a fat source (eggs, avocado, full-fat yogurt). Absorption from empty-stomach administration is poor and unpredictable.

How long does it take to normalize vitamin D levels with supplementation?

For patients with moderate deficiency (15–30 ng/mL) starting 4,000–5,000 IU D3 daily, serum 25-OH-D typically rises to the 50–70 ng/mL range within 8–12 weeks. The rise is slower in obese patients due to adipose sequestration. For severely deficient patients (below 15 ng/mL), a loading protocol of 10,000 IU daily or 50,000 IU weekly for 8 weeks may be used under physician supervision to accelerate repletion, followed by a maintenance dose. The key practical point: do not test too early. Serum 25-OH-D should be measured no sooner than 8 weeks after starting or changing a dose to allow adequate time for the storage pool to equilibrate.

Sources

1. Holick MF, et al. Vitamin D deficiency. New England Journal of Medicine. 2007;357(3):266-281. doi:10.1056/NEJMra070553
2. Manson JE, et al. (VITAL Research Group). Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33-44. doi:10.1056/NEJMoa1809944
3. Hahn J, et al. Vitamin D and marine omega-3 fatty acid supplementation and incident autoimmune disease. BMJ. 2022;376:e066452. doi:10.1136/bmj-2021-066452
4. Littlejohns TJ, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014;83(10):920-928. doi:10.1212/WNL.0000000000000755
5. Martineau AR, et al. Vitamin D supplementation to prevent acute respiratory tract infections. BMJ. 2017;356:i6583. doi:10.1136/bmj.i6583
6. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol. 1980;9(3):227-231. doi:10.1093/ije/9.3.227

Related Articles

• Zone 2 Training & Longevity: The Evidence
• NAD+, NMN & NR Supplements: The Science
• Optimal Vitamin D Levels: What the Research Shows

Dive Deeper into Longevity

• Sleep & Longevity
• Gut Microbiome & Longevity: Bacterial Allies
• Magnesium & Longevity
• Omega-3 Fatty Acids & Longevity